Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine...

Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma ( Dr Lin-Quan Tang - Sun Yat-sen University, Guangzhou, China )

TALA + ENZA demonstrates an improvement in rPFS vs standard of care ENZA as 1L...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

TALA + ENZA demonstrates an improvement in rPFS vs standard of care ENZA as 1L treatment for mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

MIBC patients undergoing radical cystectomy and ELND show increased node yield...

Dr Seth Lerner - Baylor College of Medicine, Houston, USA

MIBC patients undergoing radical cystectomy and ELND show increased node yield but no significant OS benefit ( Dr Seth Lerner - Baylor College of Medicine, Houston, USA )

Dostarlimab chemo combo for primary advanced or recurrent endometrial cancer

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combo for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

2L triple metronomic chemo has an OS and PFS advantage over systemic therapy...

Dr Rushabh Kiran Kothari - Tata Memorial Hospital, Mumbai, India

2L triple metronomic chemo has an OS and PFS advantage over systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari - Tata Memorial Hospital, Mumbai, India )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Single cilta-cel infusion improved PFS vs SOC in lenalidomide-refractory MM

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Single cilta-cel infusion improved PFS vs SOC in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment no benefit and...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

Cabozantinib + nivolumab/ipilimumab shows superior efficacy vs cabozantinib...

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA

Cabozantinib + nivolumab/ipilimumab shows superior efficacy vs cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )

More from ecancer